title: Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study.
abstract: Prevention of invasive fungal infections (IFIs) in orthotopic liver transplant (OLT) recipients utilizing postoperative systemic antifungal prophylaxis, typically with fluconazole, is justified among those at high risk for IFI. Use of postoperative antifungal prophylaxis for low-risk OLT recipients is widely practiced but not universally accepted nor supported by data. We conducted a prospective observational study among 200 OLT recipients who were at low risk for IFI and did not receive postoperative antifungal prophylaxis. Patients were considered low risk if they had </=1 of the following conditions: choledochojejunostomy anastomosis; retransplantation; intra-operative administration of >/=units of 40 blood products or return to the operating room for intra-abdominal bleeding; return to the operating room for anastomotic leak or vascular insufficiency; preoperative serum creatinine of >/=2 mg/dL; and perioperative Candida colonization. Patients were followed 100 d post-transplantation for evidence of IFI. Of 193 eligible patients, 7 (4%) developed an IFI. Three (2%) IFIs were due to Candida spp. and potentially preventable by standard fluconazole prophylaxis. Three patients developed invasive aspergillosis; one developed late onset disseminated cryptococcosis. Liver transplant recipients at low risk for IFI can be identified utilizing pre-determined criteria, and post-transplantation antifungal prophylaxis can be routinely withheld in these patients.
authors.affiliation: University of Alabama at Birmingham Medical Center, Madison, WI. pappas@uab.edu
authors.forename: P G
authors.initials: PG
authors.lastname: Pappas
authors.forename: D
authors.initials: D
authors.lastname: Andes
authors.forename: M
authors.initials: M
authors.lastname: Schuster
authors.forename: S
authors.initials: S
authors.lastname: Hadley
authors.forename: J
authors.initials: J
authors.lastname: Rabkin
authors.forename: R M
authors.initials: RM
authors.lastname: Merion
authors.forename: C A
authors.initials: CA
authors.lastname: Kauffman
authors.forename: C
authors.initials: C
authors.lastname: Huckabee
authors.forename: G A
authors.initials: GA
authors.lastname: Cloud
authors.forename: W E
authors.initials: WE
authors.lastname: Dismukes
authors.forename: A W
authors.initials: AW
authors.lastname: Karchmer
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D005006:Ethnicity; D005260:Female; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000145:classification / Q000188:drug therapy / Q000453:epidemiology*; D011183:Postoperative Complications / Q000382:microbiology*; D011446:Prospective Studies; D016019:Survival Analysis; D014481:United States
chemical_list: D000935:Antifungal Agents